Multicenter performance assessment of Carba NP test

Scott A. Cunningham; Brandi Limbago; Maria Traczewski; Karen Anderson; Meredith Hackel; Janet Hindler; Dan Sahm; Efe Alyanak; Adrian Lawsin; Christopher A. Gulvik; Tom J.B. De Man; Jayawant N. Mandrekar; Audrey N. Schuetz; Stephen Jenkins; Romney Humphries; Elizabeth Palavecino; Shawn Vasoo; Robin Patel

doi:10.1128/JCM.00244-17

Multicenter performance assessment of Carba NP test

Scott A. Cunningham, Brandi Limbago, Maria Traczewski, Karen Anderson, Meredith Hackel, Janet Hindler, Dan Sahm, Efe Alyanak, Adrian Lawsin, Christopher A. Gulvik, Tom J.B. De Man, Jayawant N. Mandrekar, Audrey N. Schuetz, Stephen Jenkins, Romney Humphries, Elizabeth Palavecino, Shawn Vasoo, Robin Patel

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Eighty Gram-negative bacilli (54 Enterobacteriaceae and 26 nonfermenting Gram-negative bacilli) obtained from multiple institutions in the United States were distributed in a blinded manner to seven testing laboratories to compare their performance of a test for detection of carbapenemase production, the Carba NP test. The Carba NP test was performed by all laboratories, following the Clinical and Laboratory Standards Institute (CLSI) procedure. Site-versus-site comparisons demonstrated a high level of consistency for the Carba NP assay, with just 3/21 site comparisons yielding a difference in sensitivity (P < 0.05). Previously described limitations with bla_OXA-48-like carbapenemases and bla_OXA carbapenemases associated with Acinetobacter baumannii were noted. Based on these data, we demonstrate that the Carba NP test, when implemented with the standardized CLSI methodology, provides reproducible results across multiple sites for detection of carbapenemases.

Original language	English (US)
Pages (from-to)	1954-1960
Number of pages	7
Journal	Journal of clinical microbiology
Volume	55
Issue number	6
DOIs	https://doi.org/10.1128/JCM.00244-17
State	Published - Jun 2017

Keywords

Antimicrobial resistance
Carbapenemase
Gram-negative bacilli
Screening

ASJC Scopus subject areas

Microbiology (medical)

Access to Document

10.1128/JCM.00244-17

Cite this

Cunningham, S. A., Limbago, B., Traczewski, M., Anderson, K., Hackel, M., Hindler, J., Sahm, D., Alyanak, E., Lawsin, A., Gulvik, C. A., De Man, T. J. B., Mandrekar, J. N., Schuetz, A. N., Jenkins, S., Humphries, R., Palavecino, E., Vasoo, S., & Patel, R. (2017). Multicenter performance assessment of Carba NP test. Journal of clinical microbiology, 55(6), 1954-1960. https://doi.org/10.1128/JCM.00244-17

Cunningham, SA, Limbago, B, Traczewski, M, Anderson, K, Hackel, M, Hindler, J, Sahm, D, Alyanak, E, Lawsin, A, Gulvik, CA, De Man, TJB, Mandrekar, JN, Schuetz, AN, Jenkins, S, Humphries, R, Palavecino, E, Vasoo, S & Patel, R 2017, 'Multicenter performance assessment of Carba NP test', Journal of clinical microbiology, vol. 55, no. 6, pp. 1954-1960. https://doi.org/10.1128/JCM.00244-17

@article{ea275a858a7948b89c33f5c7dcd4abc9,

title = "Multicenter performance assessment of Carba NP test",

abstract = "Eighty Gram-negative bacilli (54 Enterobacteriaceae and 26 nonfermenting Gram-negative bacilli) obtained from multiple institutions in the United States were distributed in a blinded manner to seven testing laboratories to compare their performance of a test for detection of carbapenemase production, the Carba NP test. The Carba NP test was performed by all laboratories, following the Clinical and Laboratory Standards Institute (CLSI) procedure. Site-versus-site comparisons demonstrated a high level of consistency for the Carba NP assay, with just 3/21 site comparisons yielding a difference in sensitivity (P < 0.05). Previously described limitations with blaOXA-48-like carbapenemases and blaOXA carbapenemases associated with Acinetobacter baumannii were noted. Based on these data, we demonstrate that the Carba NP test, when implemented with the standardized CLSI methodology, provides reproducible results across multiple sites for detection of carbapenemases.",

keywords = "Antimicrobial resistance, Carbapenemase, Gram-negative bacilli, Screening",

author = "Cunningham, {Scott A.} and Brandi Limbago and Maria Traczewski and Karen Anderson and Meredith Hackel and Janet Hindler and Dan Sahm and Efe Alyanak and Adrian Lawsin and Gulvik, {Christopher A.} and {De Man}, {Tom J.B.} and Mandrekar, {Jayawant N.} and Schuetz, {Audrey N.} and Stephen Jenkins and Romney Humphries and Elizabeth Palavecino and Shawn Vasoo and Robin Patel",

year = "2017",

month = jun,

doi = "10.1128/JCM.00244-17",

language = "English (US)",

volume = "55",

pages = "1954--1960",

journal = "Journal of clinical microbiology",

issn = "0095-1137",

publisher = "American Society for Microbiology",

number = "6",

}

TY - JOUR

T1 - Multicenter performance assessment of Carba NP test

AU - Cunningham, Scott A.

AU - Limbago, Brandi

AU - Traczewski, Maria

AU - Anderson, Karen

AU - Hackel, Meredith

AU - Hindler, Janet

AU - Sahm, Dan

AU - Alyanak, Efe

AU - Lawsin, Adrian

AU - Gulvik, Christopher A.

AU - De Man, Tom J.B.

AU - Mandrekar, Jayawant N.

AU - Schuetz, Audrey N.

AU - Jenkins, Stephen

AU - Humphries, Romney

AU - Palavecino, Elizabeth

AU - Vasoo, Shawn

AU - Patel, Robin

PY - 2017/6

Y1 - 2017/6

N2 - Eighty Gram-negative bacilli (54 Enterobacteriaceae and 26 nonfermenting Gram-negative bacilli) obtained from multiple institutions in the United States were distributed in a blinded manner to seven testing laboratories to compare their performance of a test for detection of carbapenemase production, the Carba NP test. The Carba NP test was performed by all laboratories, following the Clinical and Laboratory Standards Institute (CLSI) procedure. Site-versus-site comparisons demonstrated a high level of consistency for the Carba NP assay, with just 3/21 site comparisons yielding a difference in sensitivity (P < 0.05). Previously described limitations with blaOXA-48-like carbapenemases and blaOXA carbapenemases associated with Acinetobacter baumannii were noted. Based on these data, we demonstrate that the Carba NP test, when implemented with the standardized CLSI methodology, provides reproducible results across multiple sites for detection of carbapenemases.

AB - Eighty Gram-negative bacilli (54 Enterobacteriaceae and 26 nonfermenting Gram-negative bacilli) obtained from multiple institutions in the United States were distributed in a blinded manner to seven testing laboratories to compare their performance of a test for detection of carbapenemase production, the Carba NP test. The Carba NP test was performed by all laboratories, following the Clinical and Laboratory Standards Institute (CLSI) procedure. Site-versus-site comparisons demonstrated a high level of consistency for the Carba NP assay, with just 3/21 site comparisons yielding a difference in sensitivity (P < 0.05). Previously described limitations with blaOXA-48-like carbapenemases and blaOXA carbapenemases associated with Acinetobacter baumannii were noted. Based on these data, we demonstrate that the Carba NP test, when implemented with the standardized CLSI methodology, provides reproducible results across multiple sites for detection of carbapenemases.

KW - Antimicrobial resistance

KW - Carbapenemase

KW - Gram-negative bacilli

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85019620148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019620148&partnerID=8YFLogxK

U2 - 10.1128/JCM.00244-17

DO - 10.1128/JCM.00244-17

M3 - Article

C2 - 28404676

AN - SCOPUS:85019620148

SN - 0095-1137

VL - 55

SP - 1954

EP - 1960

JO - Journal of clinical microbiology

JF - Journal of clinical microbiology

IS - 6

ER -

Multicenter performance assessment of Carba NP test

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this